- Home
- JKHY vs PTGX Comparison
JKHY vs PTGX Comparison
Compare JKHY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | PTGX |
|---|---|---|
| Founded | 1976 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | JKHY | PTGX |
|---|---|---|
| Price | $153.68 | $136.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $197.25 | $108.23 |
| AVG Volume (30 Days) | ★ 1.1M | 602.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 19.31 | N/A |
| EPS | ★ 5.41 | 0.05 |
| Revenue | ★ $1,536,603,000.00 | N/A |
| Revenue This Year | $8.03 | $874.25 |
| Revenue Next Year | $6.39 | N/A |
| P/E Ratio | ★ $28.47 | $2,732.80 |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $121.04 | $50.49 |
| 52 Week High | $193.39 | $143.29 |
Technical Indicators
Market Signals| Indicator | JKHY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 55.39 |
| Support Level | $146.28 | $94.48 |
| Resistance Level | $157.87 | $142.20 |
| Average True Range (ATR) | 4.52 | 6.47 |
| MACD | 0.13 | -1.04 |
| Stochastic Oscillator | 48.06 | 49.08 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.